DW-MRI Assessment of Cancer Response to Chemoradiation
MR imaging is widely used in the radiological diagnosis of oncology patients as it provides excellent soft tissue differentiation using routine anatomical MR imaging. A variety of MR acquisition sequences are available which can yield images of biophysica
- PDF / 5,456,233 Bytes
- 18 Pages / 565.087 x 783.354 pts Page_size
- 17 Downloads / 173 Views
CONTENTS
SUMMARY 10.1
Overview of Current Cancer Treatment Response Assessment 157
10.2
Introduction of DW-MRI for Cancer Treatment Response Assessment 158
10.3
DW-MRI as a Clinical Biomarker of Cancer Treatment Response 161
10.4
Assessment of Tumour Response Using DW-MRI 161 10.4.1 Liver Tumours 161 10.4.2 Nodal Disease 163 10.4.3 Breast Cancer 163 10.4.4 Tumours of the Central Nervous System 164 10.4.5 Bone Malignancies 165 10.4.5.1 Primary Bone Tumours 166 10.4.5.2 Metastatic Cancers 167 10.4.6 Soft Tissue Sarcomas 167 10.4.7 Squamous Cell Carcinoma of the Head and Neck 169 10.4.8 Cervical Cancer 169 10.4.9 Rectal Cancers 171 10.5
Summary 172
References
172
MR imaging is widely used in the radiological diagnosis of oncology patients as it provides excellent soft tissue differentiation using routine anatomical MR imaging. A variety of MR acquisition sequences are available which can yield images of biophysical, physiological, metabolic, or functional properties of tissues. Imaging of response to oncological treatments has traditionally used single or multidirectional measurements of tumour dimensions following completion of therapy. Development of an MR imaging biomarker that would allow for early prediction of tumour response to therapeutic intervention would be a significant achievement as it could individualize clinical management of cancer patients in a timely fashion and improve outcome. This goal is very important as standard risk factors currently used in patient assessment cannot account for the variable and unpredictable treatment responses encountered by patients with similar risk profiles. This chapter will overview the use of diffusion-weighted MR imaging (DW-MRI) as a method of providing a potentially early surrogate marker of response to therapy in oncological imaging.
10.1 Overview of Current Cancer Treatment Response Assessment
Brian D. RoSS, PhD Craig J. Galbán, PhD Alnawaz Rehemtulla, PhD Department of Radiology, Center for Molecular Imaging, 109 Zina Pitcher Place , Ann Arbor, MI 48109-2200, USA
Management of patients with solid malignancies involves the diagnosis, treatment planning, and assessment of treatment response or recurrence. MR imaging plays a key role in patient management, as it is able to provide cross-sectional images and threedimensional acquisition of anatomical regions, thus
10
158
B. D. Ross, C. J. Galbán, and A. Rehemtulla
allowing precise radiographic measurements of tumour location and size. However, reaching a consensus on how tumour boundaries should be optimally defined or how tumour response/progression should be scored is still a subject of debate. While a single method to determine tumour response has not been developed, solid tumour response based on a single linear summation of selected target lesions, termed “response evaluation criteria in solid tumours” (RECIST) (Therasse et al. 2000), has been widely adopted for clinical protocols. This method of linear summation has gained acceptance as it provides for a relatively rapid and reproducible approa
Data Loading...
